M-14014 Cytokeratin Fragment Antigen (Cyfra21-1) Quantitative Test Kit

Clinical Significance:
Serum Cyfra21-1 levels are elevated in squamous cell carcinoma, non-small cell lung cancer, large cell lung cancer, lung cancer, adenocarcinoma, small cell lung cancer, and metastatic lung cancer.
Elevated serum Cyfra21-1 levels are also observed in cervical cancer, ovarian cancer, breast cancer, bladder cancer, prostate cancer, pancreatic cancer, gastric cancer, colorectal cancer, and liver cancer.
Serum Cyfra21-1 levels correlate with the extent of tumor progression and histological classification.
Product Specifications: 20 tests per box
Product Shelf Life: Sealed in an aluminum foil bag, the product is valid for 18 months. Once opened, the aluminum foil bag should be used within 1 hour.
Product Storage: Store the test cards at 2°C to 30°C.
 
Usage Scenarios:
Hospitals and Oncology Departments: For diagnosing and monitoring various cancers such as squamous cell carcinoma, non-small cell lung cancer, large cell lung cancer, adenocarcinoma, small cell lung cancer, and metastatic lung cancer by tracking Cyfra21-1 levels.
Diagnostic Laboratories: For routine testing of serum Cyfra21-1 levels to aid in the diagnosis and management of multiple malignancies, including cervical, ovarian, breast, bladder, prostate, pancreatic, gastric, colorectal, and liver cancers.
Cancer Screening Programs: For regular screening and monitoring of high-risk populations for early detection of cancers associated with elevated Cyfra21-1 levels.
Gynecology and Gastroenterology Clinics: For differential diagnosis and monitoring of malignancies in the cervix, ovaries, gastrointestinal tract, and other organs.
Suitable Countries and Regions:
Developed Countries: United States, Canada, Western Europe (e.g., Germany, France, UK), Japan, Australia, etc., where advanced diagnostic tools are widely used for comprehensive cancer management and early detection.
Emerging Markets: China, India, Southeast Asia, Latin America, Eastern Europe, Middle East, etc., where healthcare systems are improving diagnostic capabilities for cancer and expanding access to modern diagnostic tools.
Global Health Programs: International health initiatives focused on enhancing cancer detection and management in low-resource settings.